News
NAMS ▲ +0.6% - NewAmsterdam Pharma Company N.V.
NAMS ▲ +0.6% - NewAmsterdam Pharma Company N.V.
$NAMS NAMSW - NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29-SEP-2026 08:03 AM ET
Share this post
More filings for $NAMS
NAMS - NewAmsterdam Pharma Company N.V. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026NAMS ▲ +4.0% - NewAmsterdam Pharma Company N.V.Nov 4, 2026NAMS ▲ +4.0% - NewAmsterdam Pharma Company N.V.Nov 4, 2026NAMS ▼ -0.5% - NewAmsterdam Pharma Company N.V.Nov 3, 2026NAMS ▼ -3.9% - NewAmsterdam Pharma Company N.V.Oct 2, 2026NAMS - NewAmsterdam Pharma Company N.V. - SEC Filing Update (22-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 22, 2026
View full $NAMS filing history →💬 Comments
Loading comments…
Leave a comment